Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10043
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarlis, Peter-
dc.contributor.authorHorrigan, Mark-
dc.contributor.authorChan, Robert K-
dc.contributor.authorAjani, Andrew E-
dc.contributor.authorProimos, George-
dc.contributor.authorSchumer, Wendy A-
dc.contributor.authorvan Gaal, William J-
dc.contributor.authorRowe, Michael-
dc.contributor.authorEccleston, David-
dc.contributor.authorYan, Bryan B P-
dc.contributor.authorMun Cheong, Yu-
dc.contributor.authorOliver, Les E-
dc.contributor.authorClark, David J-
dc.date.accessioned2015-05-15T23:22:22Z
dc.date.available2015-05-15T23:22:22Z
dc.date.issued2005-10-12-
dc.identifier.citationCardiovascular Revascularization Medicine : Including Molecular Interventions; 6(4): 179-81en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10043en
dc.description.abstractIn-stent restenosis (ISR) remains a challenging problem in percutaneous coronary intervention and the optimal treatment strategy remains unclear. The aim of this study was to compare the 18 month clinical outcomes in patients receiving sirolimus-eluting stents (SES) with vascular brachytherapy (VBT) for the treatment of ISR. Twenty-five consecutive patients treated with VBT were compared with 29 patients who had SES deployment for ISR. Major adverse cardiac events (MACE) were defined as a combination of death from cardiac causes, nonfatal myocardial infarction, or repeat TVR. At 18 month follow-up, the MACE rate was significantly lower in the SES compared with the VBT group (14% vs 40%, P=.03). One patient in the VBT group developed late stent thrombosis (at 10 months) and died; there was no stent thrombosis in the SES group. This observational study, taken with other recent reports, offers further credence to the use of SES for ISR. The results of randomized comparisons with VBT are awaited with interest.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherBlood Vessel Prosthesis Implantation.instrumentationen
dc.subject.otherBrachytherapy.methodsen
dc.subject.otherCoated Materials, Biocompatibleen
dc.subject.otherCoronary Angiographyen
dc.subject.otherCoronary Restenosis.radiography.therapy.ultrasonographyen
dc.subject.otherDecision Makingen
dc.subject.otherEndosonographyen
dc.subject.otherFemaleen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherHumansen
dc.subject.otherImmunosuppressive Agents.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherRetrospective Studiesen
dc.subject.otherSirolimus.therapeutic useen
dc.subject.otherStentsen
dc.subject.otherTreatment Outcomeen
dc.titleWhat is the best contemporary treatment for in-stent restenosis?en
dc.typeJournal Articleen
dc.identifier.journaltitleCardiovascular revascularization medicine : including molecular interventionsen
dc.identifier.affiliationDepartment of Cardiology, Austin Hospital, Studley Road, PO Box 5555, Heidelberg, Victoria 3084, Australiaen
dc.identifier.doi10.1016/j.carrev.2005.10.001en
dc.description.pages179-81en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/16326381en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherChan, Robert K
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptCardiology-
crisitem.author.deptCardiology-
crisitem.author.deptCardiology-
crisitem.author.deptUniversity of Melbourne Clinical School-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Feb 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.